Gemfibrozil
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
The txgnn-pipeline skill is noted. This task is report generation from an Evidence Pack — I'll apply the report format specification in the system prompt directly.
Gemfibrozil: From Hypertriglyceridemia to Rheumatoid Arthritis
One-Sentence Summary
Gemfibrozil is a fibrate-class lipid-lowering agent (PPARα agonist) classically used for the management of hypertriglyceridemia and mixed dyslipidemia. The TxGNN model predicts it may be effective for Rheumatoid Arthritis (RA), with 0 clinical trials and 4 publications currently supporting this direction — evidence is at an early, preclinical stage. The biological rationale centres on PPARα-mediated suppression of inflammatory cytokines, but human-level validation is entirely absent.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertriglyceridemia / Dyslipidemia (fibrate class; no Italy registration on record) |
| Predicted New Indication | Rheumatoid Arthritis |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L4 |
| Italy Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the current Evidence Pack. Based on well-established pharmacology, gemfibrozil is a PPARα (peroxisome proliferator-activated receptor alpha) agonist of the fibrate class. Its classical role is to reduce serum triglycerides and raise HDL cholesterol by increasing lipoprotein lipase activity and reducing hepatic VLDL secretion.
The anti-inflammatory bridge to rheumatoid arthritis is mechanistically plausible. PPARα activation suppresses NF-κB signalling, which is the master transcription factor driving synovial inflammation in RA. Downstream consequences include downregulation of TNF-α, IL-6, and IL-1β — the very cytokines that biologics such as adalimumab and tocilizumab are designed to block. Additionally, fibrate-class compounds with partial PPARγ co-agonism can inhibit osteoclast differentiation, potentially limiting the bone erosion that defines progressive RA.
The most direct supporting evidence comes from a 2019 rat adjuvant-induced arthritis (AIA) model study (PMID 30074417), which found that gemfibrozil combined with reduced-dose prednisolone achieved arthritis control equivalent to full-dose prednisolone — suggesting a steroid-sparing effect. A 2026 collagen-induced arthritis (CIA) study of bezafibrate, another fibrate, further validates the fibrate class mechanism via PPAR-γ-dependent immune modulation (PMID 41207105). However, these are animal models, and extrapolation to human RA requires dedicated clinical investigation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30074417 | 2019 | Animal study (AIA model) | Modern Rheumatology | Gemfibrozil (30 mg/kg) combined with reduced-dose prednisolone achieved arthritis control comparable to full-dose prednisolone in a rat AIA model; supports steroid-sparing potential via PPARα |
| 41207105 | 2026 | Animal study (CIA model) | Int Immunopharmacology | Bezafibrate (pan-PPAR agonist) attenuated experimental RA via PPAR-γ-dependent modulation of inflammatory pathways; demonstrates fibrate class anti-arthritic mechanism |
| 20083653 | 2010 | Mechanistic study | J Immunology | Nitric oxide downregulates Foxp3 in regulatory T cells following MBP priming; provides mechanistic context for immune dysregulation in autoimmune disease relevant to RA pathophysiology |
| 18039017 | 2007 | Review | Am J Clin Dermatology | Palmar erythema as a secondary marker of systemic pathology including RA; indirect relevance only — not a gemfibrozil study |
Safety Considerations
Please refer to the package insert for safety information.
Note: Two data gaps were identified in this Evidence Pack that directly affect safety evaluation: (1) Italy/TFDA package insert warnings and contraindications were not retrieved (DG001, Severity: Blocking); (2) Formal MOA data from DrugBank is absent (DG002, Severity: High). Both must be resolved before any clinical safety assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence supporting gemfibrozil for rheumatoid arthritis is limited exclusively to animal models and mechanistic studies (L4), with no human clinical trials registered and no controlled human data. Although the PPARα → NF-κB → cytokine suppression pathway is biologically coherent, the gap between rodent AIA models and clinical RA is substantial and well-documented.
To proceed, the following is needed:
- Resolve DG001 (Blocking): Retrieve Italy/TFDA package insert to establish contraindications and key warnings before any safety evaluation
- Resolve DG002 (High): Confirm full DrugBank MOA profile for gemfibrozil, including known pharmacodynamic interactions with RA co-medications (DMARDs, NSAIDs, biologics)
- DDI risk assessment: Gemfibrozil is a strong CYP2C8 inhibitor — evaluate interaction potential with methotrexate and other RA standard-of-care agents
- Preclinical specificity: Commission gemfibrozil-specific (not class-level) synovial cell line studies and dose-response characterisation in CIA model
- Comparative positioning: Justify gemfibrozil over bezafibrate or fenofibrate, both of which have stronger or more recent animal RA evidence
- Regulatory feasibility: Assess whether the Italy (AIFA) off-label or compassionate use pathway applies given zero domestic market authorisations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.